Chester County News and Community Website
RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) has achieved a significant milestone in the development of its antidepressant drug, NRX-100 (Ketamine). On September 24, 2024, the company announced that the …
NRx Pharmaceuticals Advances Towards FDA Approval with Key Stability Milestone for NRX-100 Read More RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) recently received attention in an article on Psychiatrist.com, which discussed the potential of its pipeline products, NRX-100 and NRX-101, in addressing bipolar depression …
NRx Pharmaceuticals’ Innovative Treatments for Depression Gain Spotlight Read More RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) has released its financial results for the second quarter and year-to-date ending June 30, 2024, along with a comprehensive business update. The company …
NRx Pharmaceuticals Reports Second Quarter and Year-to-Date 2024 Financial Results and Business Update Read More RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) recently secured up to $16 million in convertible debt financing from an institutional investor. The company plans to use the funds to …
NRx Pharmaceuticals Secures $16 Million in Convertible Debt Financing Read More RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) announced that the U.S. Food and Drug Administration (FDA) has provided positive feedback and alignment on its proposed initial Pediatric Study Plan …
FDA Aligns with NRx Pharmaceuticals on Pediatric Study for Suicidal Depression Treatment Read More
RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) has received a favorable ruling from a Utah arbitrator, allowing the company to move forward with its planned spinoff of 49% of …
NRx Pharmaceuticals Wins Arbitration to Proceed with HOPE Therapeutics Spinoff Read More RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) recently announced plans to file two New Drug Applications (NDAs) in 2024. The filings, supported by advice from regulatory counsel including former …
NRx Pharmaceuticals Plans to File Two New Drug Applications in 2024 Read More RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) announced that its management team will participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024.
NRx Pharmaceuticals to Participate in H.C. Wainwright Neuro Perspectives Conference Read More RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) recenlty appointed Dr. Dennis McBride to its Board of Directors. Dr. McBride brings a wealth of experience in neuroscience, medical technology, and …
NRx Pharmaceuticals Welcomes Dr. Dennis McBride to Board Read More RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) has posted a new Shareholder Update Letter on its website, inviting interested parties to subscribe to their email alert service for ongoing …
NRx Pharmaceuticals Highlights Ketamine’s Role in Depression Treatment Read More